Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-509 dose-ranging phase 2 study in active rheumatoid arthritis on stable methotrexate
2011-004419-22Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of decernotinib in rheumatoid arthritis (RA) (3 arms), sponsored by Vertex Pharmaceuticals. Started Mar 2012; status: completed.
02
Drugs
decernotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-004419-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004419-22.